A biodiffusion chamber for performing autologous cell vaccination is provided. The biodiffusion chamber is adapted for insertion into and removal from a subject. In some embodiments, the biodiffusion chamber comprises (i) a chamber body defining a hollow cavity and including a first surface and a second surface, (ii) a first semi-permeable membrane coupled to the first surface, (iii) a second semi-permeable membrane coupled to the second surface, and (iv) an element and/or feature adapted for removing the biodiffusion chamber from the subject. The first semi-permeable membrane and the second semi-permeable membrane are permeable to fluids and soluble factors but are not permeable to cells. In some embodiments, composition comprising a therapeutically effective amount of an antisense oligodeoxynucleotide is inserted into the biodiffusion chamber and allowed to diffuse out of the biodiffusion chamber and into the subject via at least one of the first semi-permeable membrane or the second semi-permeable membrane.

An intravascular port is provided. The intravascular port includes a housing having an internal chamber and an outer body having a membrane on a surface thereof, the housing including one or more access openings that communicate with the internal chamber. One or more sensors are received within the one or more access openings for sensing one or more physiological parameters of a patient. One or more treatment units are received within the internal chamber of the intravascular port for providing a treatment protocol including medications to the patient. A control unit is in communication with the one or more sensors and the one or more treatment units and is configured to receive a signal from the one or more sensors and output a treatment protocol to the patient.

A medical device configured to improve medicament dispersion within a cerebrospinal fluid of a patient. The medical device including an implantable catheter having a distal end configured to be positioned within a flow of the cerebrospinal fluid, a proximal end, a body defining a lumen extending lengthwise along the implantable catheter configured to enable a flow of medicament from the proximal end to an infusion port located in proximity to the distal end, and a piezoelectric element positioned in proximity to the infusion port configured to selectively oscillate during medicament administration to improve dispersion of the medicament within the cerebrospinal fluid.

Endovascular drug delivery systems and methods are disclosed herein for delivering a therapeutic agent to the intracranial subarachnoid space of a patient, and/or deploying an endovascular drug delivery device distal portion in the intracranial subarachnoid space and a portion of the drug delivery device body in a dural venous sinus such that a therapeutic agent is delivered from the deployed drug delivery device into the intracranial subarachnoid space.

A lubrication device for lubricating a joint of a human or mammal patient, which is entirely implantable in a patient's body, comprises a reservoir for storing a lubricating fluid and a fluid connection for introducing the lubricating fluid into the joint when the device is implanted in the patient's body. Further, the fluid connection comprises a fluid connection device connecting the reservoir with the joint such that a lubricating fluid flow is established from the reservoir into the joint. The fluid connection comprises either an infusion needle adapted to be intermittently placed into the joint for injecting the lubricating fluid, or a tube adapted to be permanently placed into the joint for continuously injecting the lubricating fluid.

In certain systems disclosed herein, one or more of a first vascular access port and a second vascular access port can be selected by a customer. Each of the first and second vascular access ports can be implanted subcutaneously within a patient, and each can include a base configured to be attached to a vessel, a body that extends away from the base, and a guidance passageway that extends through the body and the base and includes a funnel region. A maximum height defined by the base and body of the second vascular access port can be greater than a maximum height defined by the base and body of the first vascular access port.

Apparatus and methods are provided to position a device at adjacent tissues near a urethra to overcome the problem of urine leakage during physical movement or activity by changing a contour of a urethra. The devices may include mechanisms such as an inflatable pouch or a pillow anchored to the adjacent tissues of a urethra by an anchoring hook. The inflation of the pouch by an external fluid flexes the pouch towards a urethra and changes the contour of the urethra. The devices may also or alternatively include one or more tissue grasping T-fasteners having forward-facing and reverse-facing barbs to anchor the tissues adjacent to a urethra and bend the contour of the urethra. The device may also include actuators, clips or spring jacks having inflatable bands. The device may include a cap, one-way valves and a combination of a plug and cap to block urethral ostium to temporarily block urine flow from a bladder.

Endovascular drug delivery systems and methods are disclosed herein for delivering a therapeutic agent to the intracranial subarachnoid space of a patient, and/or deploying an endovascular drug delivery device distal portion in the intracranial subarachnoid space and a portion of the drug delivery device body in a dural venous sinus such that a therapeutic agent is delivered from the deployed drug delivery device into the intracranial subarachnoid space.

A therapeutic agent injection device including an injection device for delivering a therapeutic agent to a patient having a body, the body having a patient face and a port face opposite the patient face, the port face having an introducer port including an introducer channel and an injection port including an injection channel, the introducer channel being in fluid communication with the injection channel through a cross channel, the injection channel defining an injection axis; a delivery tube for subcutaneous delivery of the therapeutic agent to the patient, the delivery tube projecting from and being generally perpendicular to the patient face, the delivery tube defining an introducer axis and being in fluid communication with the injection port; and a patch, the patch being attached to the patient face and being operable to adhesively attach to the patient; wherein the injection axis is parallel to the introducer axis.

A subcutaneous implantable device for guiding a vascular access member, the device including a channel defined by a through-hole in the device, wherein the channel is configured to guide the vascular access member there-through to a vascular site; and anchoring means adapted for fixedly attaching, in a form of using suture, tissue ingrowth, tissue encapsulation or tissue adhesion, the device to at least one of a dermis or a subcutaneous tissue at a position underneath the dermis to allow repeated access of the vascular access member through the channel to the vascular site, wherein the device is dimensioned to allow the device to be attached through the anchoring means for anchoring the entire device at a distance away from the vascular site, A method of creating scar tissue track for vascular access is also disclosed where the subcutaneous implantable device for guiding vascular access member is first implanted sub-dermally, the dermis is palpated to feel for the device location and orientation, the guiding channel is accessed using the sharp vascular access member and following the angle of the guiding channel to access the vascular site and repeating the steps till scarred tissue track is created and finally, switching the sharp vascular access member to a blunt vascular access member to access the vascular site via the scarred tissue track.